Marinus Pharmaceuticals Inc

NASDAQ:MRNS   3:59:42 PM EDT
13.54
-0.50 (-3.56%)
Products, Regulatory

Marinus Provides Corporate Update On Phase 3 Raise Trial In Status Epilepticus

Published: 09/24/2020 20:09 GMT
Marinus Pharmaceuticals Inc (MRNS) - Marinus Provides Corporate Update on Phase 3 Raise Trial in Status Epilepticus (se).
Marinus Pharmaceuticals Inc - Satisfied FDA's Protocol-specific Questions for Phase 3 Trial in Refractory Status Epilepticus.
Marinus Pharmaceuticals Inc - Intends to Begin Enrollment for Registrational Phase 3 Clinical Trial in Rse.
Marinus Pharmaceuticals Inc - Over 55 Out of Projected 80 Sites Have Been Selected for Trial Participation.
Marinus Pharmaceuticals Inc - Continues to Anticipate Top-line Data From Phase 3 Raise Trial in 1h 2022.